New sublingual film could make opioid withdrawal less miserable
NCT ID NCT05712707
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new sublingual film called BXCL501 (dexmedetomidine) to reduce the unpleasant symptoms of opioid withdrawal, like anxiety, muscle pain, and nausea. About 160 adults with opioid use disorder will receive the drug, a placebo, or an existing medication (lofexidine) during a 7-day inpatient stay. The goal is to see if BXCL501 is safer and works better than current options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BXCL501 (dexmedetomidine sublingual film)
What this could lead to
If successful, this could offer a safer, non-opioid option to manage withdrawal symptoms and help people start treatment for opioid use disorder.
What could go wrong
This is an early-phase trial with only 160 participants, and one site is paused. The drug may not prove safer or more effective than existing options like lofexidine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CenExel HRI
Marlton, New Jersey, 08053, United States
-
Clinilabs
Eatontown, New Jersey, 07724, United States
-
New York State Psychiatric Institute
New York, New York, 10032, United States
-
Yale University
New Haven, Connecticut, 06519, United States